Physician profile
Karen Sein Ohn
NPI 1518119536
$2,985.08
in general payments reported to CMS, 2019-2025
22 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $340 · 2022: $317 · 2023: $873 · 2024: $1,154 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,328.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,279.74 | 2021-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $294.68 | 2023-2024 | Stelara, Tremfya |
| Pfizer INC. | $199.67 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.55 | 2021-2024 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $184.46 | 2022-2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $143.71 | 2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Gilead Sciences, INC. | $108.22 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $105.08 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $57.92 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $54.09 | 2022-2025 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $54.03 | 2024 | Resmetirom |
| Celgene Corporation | $31.30 | 2022 | |
| Ethicon US, LLC | $22.28 | 2022 | |
| Celltrion USA INC. | $20.03 | 2025 | Vegzelma |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.50 | 2022 | |
| Exact Sciences Corporation | $18.21 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $17.19 | 2021 | |
| Qol Medical, LLC | $15.94 | 2024 | Sucraid |
| Nestle Healthcare Nutrition INC. | $15.51 | 2023 | |
| Redhill Biopharma INC. | $13.31 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $7.66 | 2023 | Cold Snares |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Sein Ohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.